Goodrx is trading 5.16% down at $3.31 in the November 4 pre-market after disclosing its first- and second-quarter 2026 financial statements should no longer be relied upon. - It cited understated Pharma Direct revenue and plans to restate results. - The SEC filing says preliminary adjustments increase reported revenue; the review remains ongoing. - Accounting and control concerns are the clearest company-specific explanation. Major U.S. indices were higher, while pre-market volume was not provided.